timothy sykes logo

Stock News

Tivic Health’s Move Into Neutropenia: A New Hope?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Tivic Health’s Move Into Neutropenia: A New Hope? Thumbnail

Tivic Health Systems Inc. stocks have been trading up by 214.0 percent amid FDA approvals and positive market sentiment.

Recent Developments in Tivic Health

  • Entolimod’s license scope has widened to include Neutropenia, with market value projected to exceed $20B by 2029.
  • Tivic Health’s agreement with Statera Biopharma includes milestone-driven payments, leveraging the success of Entolimod.
  • Excellent news for investors as Tivic regains compliance with NASDAQ, stabilizing its market positioning.
  • The expansion in Entolimod’s use involves a strategic push toward commercial-grade manufacturing and FDA approvals.
  • Tivic’s stock had a previous setback, with shares dropping 8.6% but now showing signs of potential stabilization.

Candlestick Chart

Live Update At 08:18:02 EST: On Tuesday, April 22, 2025 Tivic Health Systems Inc. stock [NASDAQ: TIVC] is trending up by 214.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

A Quick Glimpse at Tivic Health’s Financials

In the world of trading, managing risk is pivotal to a successful strategy. Many traders emphasize the importance of cutting losses quickly to preserve capital. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This principle underlines the significance of not holding onto losing positions, as it can prevent a trader from incurring further losses. By adhering to this mindset, traders may reinforce a disciplined approach that prioritizes financial preservation and long-term success in volatile markets.

Tivic Health Systems is navigating turbulent financial waters. Recent earnings hint at challenges, yet there’s a glimmer of hope. Revenue hovers around $780,000 – a modest number, which reflects ongoing hurdles. But what’s striking is the array of figures unveiling Tivic’s monetary health.

Take, for example, the EBIT margin; it tumbles at a shocking -725.8%. In plain terms, Tivic is haemorrhaging funds. It’s evident in their financial statements, where total earnings from ongoing operations noted a hefty $1.47M loss. The gross profit stands at -$239,000, a number no investor wants to see.

How about assets? With current liabilities of $272,000 against a hefty $2,639,000 in available assets, Tivic stays afloat, dodging major debt pitfalls. Their solid current ratio of 9.7 signifies an ability to handle obligations in the near term.

Yet, the past weeks held both triumphs and trials for their stock performance. April 14 saw shares drop, closing at $4.29, before withering to $3.82 on April 15. But, that was before today’s promising leap, courtesy of Entolimod’s expanded prospects.

More Breaking News

High-intensity trading days litter the chart; take April 7 when shares dipped to $4.4, while April 9 witnessed a stark contrast with shares leaping to $4.82, a fascinating testament to market fickleness. What’s more, during one hectic market blip, shares sprung from $3.33 to $5.59 in a single day.

Expansion Strategy: Opportunities and Risks

Tivic’s bold leap into Neutropenia treatment territory heralds a notable pivot in its strategic direction. Entolimod’s expanded application features at the heart of this venture, countering both acute radiation syndrome and Neutropenia—winning potential market traction.

However, this transformative move is tethered to meticulous execution and regulatory compliance. Relying on partnerships, such as with Statera Biopharma, Tivic aims to realize milestones linked to commercial success.

Potential bumps in the road may arise from regulatory snafus or competition, given the crowded arena of biotech firms eager to cash in on similar promising markets.

Conclusion: Tivic’s Path Forward

Tivic Health Systems finds itself at a crucial crossroads—but not without the means to thrive. Their vast landscape—investments in new treatments and compliance triumphs—offer room for optimism.

Nonetheless, their fiscal journey is steeped in red, emphasizing caution. Trader sentiment hinges on sustained progress and strategic execution in tapping into the Neutropenia market. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This wisdom serves as a reminder for those watching Tivic Health’s next moves closely.

The story of Tivic Health has unfolded in bursts of ambition, improvement, and challenge, much like their volatile stock behavior. As they steer through the storm, the future hangs in a delicate balance of innovation and prudent financial management. Their venture into Neutropenia could well be the stride needed to redefine their place in the market.

This content is produced using automated systems designed to deliver timely stock news. All material is reviewed by our editorial team and is provided solely for informational and entertainment purposes. It does not constitute professional investment advice. For additional details, please refer to our [Terms of Service]

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”